AUG 11, 2026 · PHASE 1 TRIAL
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
ClinicalTrials.gov
This is a Phase 1 dose-escalation trial registration with no reported results; it is designed to establish safety and recommended phase 2 dose, with preliminary efficacy assessment as secondary aims.
Reported
Estimated enrollment100
PhasePHASE 1
Primary outcome measure 1Recommended phase 2 dose (RP2D) based on do…